3rd World Conference on

Breast and Cervical Cancer

September 24-25, 2018 | Abu Dhabi, UAE
Monday 24th September 2018

Day 1

09:00-09:30 Registration Opens

Andromeda

09:30-10:00 Opening Ceremony

Introduction

Keynote Presentation
Title: Cross facility collaboration: The key to winning the fight against cancer
Feroz Agad, SAH Global & SAH Care, USA

10:00-11:00 Networking and Refreshments Break with Group Photo


Session Chair: Femi Ogunremi, National Health Service (NHS), United Kingdom
Session Co-Chair: Wijdan Alomaim, Al Mafraq Hospital, UAE

Title: Setting up an oncoplastic forum; optimising patient pathway
Hazem Khout, Nottingham Breast Institute, United Kingdom

Title: Breast cancer family history assessment and counselling
Mohamad Al-Gailani, Al Hammadi Hospital, Saudi Arabia

Title: Arc therapy versus 3D-CRT in accelerated partial breast irradiation.
George Farha, Gustave Roussy Cancer Campus, France

11:30-12:00 Lunch Break 13:00-14:00 @ Assymetri Restaurant

12:00-12:30

12:30-13:00

Title: Analysis of the correlation between HLA phenotype and prognosis, and the role of a novel tumor antigen useful for immunotherapy
Yoshika Nagata, Shonan Kamakura General Hospital, Japan

Title: Galectin -3 contribute for drug resistance and EMT in TNBC
Jeethy Ram, Regional Cancer Centre, India

14:00-14:30 Panel Discussion

14:30-15:00 Networking and Refreshments Break 15:00-15:30 @ Foyer

15:30-16:00

16:00-16:30

16:30-17:00

Title: Analysis of the correlation between HLA phenotype and prognosis, and the role of a novel tumor antigen useful for immunotherapy
Yoshika Nagata, Shonan Kamakura General Hospital, Japan

Title: Diabetes & breast cancer- The unsettled link
Mahir Jallo, Gulf Medical University, UAE

Title: Synchronous breast plasmacytoma
Roaa Abdullah Attieh, King Abdullah Medical City, Saudi Arabia
Tuesday 25th September 2018
Day 2

Andromeda

09:00-10:00

Keynote Presentation
Title: The most updated theory with supporting data for cancer invasion and metastasis
Yan Gao Man, International Union for Difficult-to-treat Diseases, USA

10:00-11:00

Keynote Presentation
Title: Epigenetics and cancer
Mariam Mohd Fatima Matar, UAE Genetic Diseases Association, UAE

Networking and Refreshments Break 11:00 -11:30 @ Foyer

Session: Chemotherapy and Cancer | Molecular Oncology in Breast Cancer | Women's Health | Cancer Vaccination | Breast and Cervical Cancer Screening | Novel Approaches to Cancer Therapeutics | Cancer Epigenomics: Beyond Genomics

Session Chair: Wijdan Alomaim, Al Mafraq Hospital, UAE
Session Co-Chair: Hazem Khout, Nottingham Breast Institute, United Kingdom

11:30-12:00

Title: New opportunity and potential for breast cancer screening on a large scale especially in poor resource area
Femi Ogunremi, National Health Service (NHS), United Kingdom

12:00-12:30

Title: Maximizing breast conserving options for treating breast cancer
Hazem Khout, Nottingham Breast Institute, United Kingdom

12:30-13:00

Title: Can we avoid ALND in limited nodal disease after SLNB?
Mouza Mohd Al Ameri, Tawam Hospital, UAE

13:00-13:30

Title: Complementary and alternative therapies in cancer: Current trends and implications for oncologists
Shilpi Roy Narad, Department of Health-Abu Dhabi, UAE

Lunch Break 13:30-14:30 @ Assymetri Restaurant

14:30-15:00

Title: Cancer survivorship: Developing a cancer survivorship program at Tawam hospital, Al Ain United Arab Emirates
Maria Aamir, Tawam Hospital, UAE

15:00-15:30

Title: Evidenced based rehabilitation following breast cancer
Shruti M Velaskar, Tata Memorial Hospital, India

Networking and Refreshments Break 15:30-16:00 @ Foyer

Video Presentation
Title: A human cytomegalovirus (HCMV) model to study the functions of HCMV encoded proteins in cancer progression
Dabbu Kumar Jaijyan, Rutgers University, USA

Poster Presentations @ 16:00 - 17:00

BCC 01
Title: Identification of a miR-1245a germline variant and its relation with early-onset breast cancer susceptibility
Lilian Jara, University of Chile, Chile

BCC 02
Title: Association and additive effects of single-nucleotide polymorphisms in pre-miR-182 and TOX3 with breast cancer susceptibility
Sebastian Morales Pison, University of Chile, Chile

BCC 03
Title: Experience of the breast biopsy site marker HydroMARK during the neoadjuvant chemotherapy
Yoshika Nagata, Shonan Kamakura General Hospital, Japan

Panel Discussion

Closing Ceremony